Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)

5.15 0 (0%)

IEX Real-Time Price

May 17, 2019 EST.

NYSE American : Healthcare

Prev Close 5.15

Price Open 5.79

Volume: 38,464

Avg Volume: 43,837

Market Cap: 9.39M

P/E Ratio -

52 Wk Range 5.01-25.95



CANF Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2019-04-15
27.36M
449,405
0.93
1.64%

2019-03-29
22.44M
1.09M
2.96
4.86%

2019-03-15
22.44M
1.09M
4.47
4.85%

2019-02-28
22.44M
426,077
1.62
1.90%




CANF Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-30
Q3 2018
N/A
-0.04 (1)
0.00
0.04

2018-08-31
Q2 2018
N/A
0.00 (1)
-0.06
-0.06

2018-06-01
Q1 2018
N/A
-0.08 (1)
-0.10
-0.02

2018-05-29
Q1 2018
N/A
-0.08 (1)
0.00
0.00

News

Can-Fite's Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA) (2019-05-20 07:00 Business Wire)

The International Liver Cancer Association (ILCA) Annual Conference has selected the Can-Fite abstract for presentation Phase III trial for Namodenoson in advanced liver cancer is now under preparation Namodenoson has both Fast Track status and Orphan Drug designation fro…

 


Statistics

Shares Outstanding: 1.82M

Top 15 Institution Percent: 8.60

Price To Sales: 3.24

Price To Book: 3.42

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -86.23

Return On Equity: -168.17

Profit Margin: N/A

Price History

Beta: 1.14

50-day Moving Avg: 10.52

200-day Moving Avg: 16.66

YTD Change: -73.18

5-day Change: -16.94

1-month Change: -31.33

3-month Change: -70.14

6-month Change: -75.82

1-year Change: -73.39

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Exchange: NYSE American

Industry: Biotechnology

Sector: Healthcare

Website: http://www.canfite.com

Can Fite Biofarma Ltd is a clinical stage biopharmaceutical company. It develops orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases.